Long-term endocrine and metabolic consequences of cancer treatment: a systematic review

J Gebauer, C Higham, T Langer, C Denzer… - Endocrine …, 2019 - academic.oup.com
The number of patients surviving≥ 5 years after initial cancer diagnosis has significantly
increased during the last decades due to considerable improvements in the treatment of …

Male hypogonadism and osteoporosis: the effects, clinical consequences, and treatment of testosterone deficiency in bone health

G Golds, D Houdek, T Arnason - International journal of …, 2017 - Wiley Online Library
It is well recognized that bone loss accelerates in hypogonadal states, with female
menopause being the classic example of sex hormones affecting the regulation of bone …

[PDF][PDF] Exercise mode specificity for preserving spine and hip bone mineral density in prostate cancer patients

RU Newton, DA Galvao, N Spry, D Joseph… - Medicine & Science in …, 2019 - iapem.gr
Exercise Mode Specificity for Preserving Spine and Hip Bone Mineral Density in Prostate
Cancer Patients Page 1 Downloaded from https://journals.lww.com/acsm-msse by …

Bone health in ageing men

K David, N Narinx, L Antonio, P Evenepoel… - Reviews in Endocrine …, 2022 - Springer
Osteoporosis does not only affect postmenopausal women, but also ageing men. The
burden of disease is projected to increase with higher life expectancy both in females and …

Fracture risk and assessment in adults with cancer

C Ye, WD Leslie - Osteoporosis International, 2023 - Springer
Individuals with cancer face unique risk factors for osteoporosis and fractures. Clinicians
must consider the additive effects of cancer-specific factors, including treatment-induced …

EAA clinical guideline on management of bone health in the andrological outpatient clinic

V Rochira, L Antonio, D Vanderschueren - Andrology, 2018 - Wiley Online Library
Male osteoporosis is now a well‐recognized medical disorder with established clinical
guidelines for both diagnosis and management. Prevention as well as management of …

Cancer cell–extrinsic roles for the androgen receptor in prostate cancer

AW Hahn, BA Siddiqui, J Leo, E Dondossola… - …, 2023 - academic.oup.com
Given the central role of the androgen receptor (AR) in prostate cancer cell biology, AR-
targeted therapies have been the backbone of prostate cancer treatment for over 50 years …

[HTML][HTML] The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation

L Cianferotti, F Bertoldo, M Carini, JA Kanis, A Lapini… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Androgen deprivation therapy is commonly employed for the treatment of non-metastatic
prostate cancer as primary or adjuvant treatment. The skeleton is greatly compromised in …

The risk of fragility fractures in men with prostate cancer treated with androgen deprivation therapy

MM van Oostwaard, CE Wyers, JHM Driessen… - Osteoporosis …, 2024 - Springer
Abstract Summary Androgen Deprivation Therapy (ADT) increases long-term fracture risk in
prostate cancer. Our study showed a higher fracture risk within six months of ADT use, and …

[HTML][HTML] Thai Osteoporosis Foundation (TOPF) position statements on management of osteoporosis

T Songpatanasilp, C Sritara… - Osteoporosis and …, 2016 - Elsevier
The adjusted incidence rate of hip fracture in Thailand has increased more than 31% from
1997 to 2006. Mortality and morbidity after hip fracture are also high. One year mortality after …